Requirement for LMP1-induced RON receptor tyrosine kinase in Epstein-Barr virus-mediated B-cell proliferation

Blood

Volumn 118, Issue 5, 2011, Pages 1340-1349

  Chou, Ya Ching ^a   Lin, Sue Jane ^b   Lu, Jean ^c   Yeh, Te Huei ^d   Chen, Chi Long ^e   Weng, Pei Lun ^a   Lin, Jiun Han ^a   Yao, Ming ^d   Tsai, Ching Hwa ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c GENOMICS RESEARCH CENTER   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; PROTEIN TYROSINE KINASE; RECEPTEUR D ORIGINE NATAIS ENZYME; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B LYMPHOCYTE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; DRUG TARGETING; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; LYMPHOBLASTOID CELL; LYMPHOPROLIFERATIVE DISEASE; MALE; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISORDER; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SCHOOL CHILD; SIGNAL TRANSDUCTION; TRANSPLANTATION;

EID: 80051554138     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-335448     Document Type: Article

References (46)

1. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, Griffin DE, et al, eds. Fields Virology, Vol 2. Hagerstown, MD: Lippincott Williams & Wilkin; 2001.
2. Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol. 2003;3(10):801-812. (Pubitemid 37328658)
3. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004;4(10):757-768. (Pubitemid 39331148)
4. Bieging KT, Swanson-Mungerson M, Amick AC, Longnecker R. Epstein-Barr virus in Burkitt's lymphoma: a role for latent membrane protein 2A. Cell Cycle. 2010;9(5):901-908.
5. Tsai SC, Lin SJ, Chen PW, et al. EBV Zta protein induces the expression of interleukin-13, promoting the proliferation of EBV-infected B cells and lymphoblastoid cell lines. Blood. 2009;114(1):109-118.
6. Alcami A. Viral mimicry of cytokines, chemokines and their receptors. Nat Rev Immunol. 2003;3(1):36-50. (Pubitemid 37328698)
7. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411(6835):355-365. (Pubitemid 32467045)
8. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103(2):211-225.
9. Martin GS. The hunting of the Src. Nat Rev Mol Cell Biol. 2001;2(6):467-475.
10. Javier RT, Butel JS. The history of tumor virology. Cancer Res. 2008;68(19):7693-7706.
11. Ronsin C, Muscatelli F, Mattei MG, Breathnach R. A novel putative receptor protein tyrosine kinase of the met family. Oncogene. 1993;8(5):1195-1202. (Pubitemid 23129841)
12. Gaudino G, Follenzi A, Naldini L, et al. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J. 1994;13(15):3524- 3532. (Pubitemid 24246189)
13. Chen YQ, Zhou YQ, Fisher JH, Wang MH. Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: oncogenic potential of RON in vivo. Oncogene. 2002;21(41):6382-6386.
14. Maggiora P, Marchio S, Stella MC, et al. Overexpression of the RON gene in human breast carcinoma. Oncogene. 1998;16(22):2927-2933. (Pubitemid 28383277)
15. Thomas RM, Toney K, Fenoglio-Preiser C, et al. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res. 2007;67(13):6075-6082. (Pubitemid 47037486)
16. Wang MH, Wang D, Chen YQ. Oncogenic and invasive potentials of human macrophagestimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis. 2003;24(8):1291-1300. (Pubitemid 37038819)
17. Xu XM, Wang D, Shen Q, Chen YQ, Wang MH. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells. Oncogene. 2004;23(52):8464-8474. (Pubitemid 39540797)
18. Wang J, Rajput A, Kan JL, et al. Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma. J Biol Chem. 2009;284(16):10912-10922.
19. Logan-Collins J, Thomas RM, Yu P, et al. Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers. Cancer Res. 2010;70(3):1130-1140.
20. Lu J, Chen SY, Chua HH, et al. Upregulation of tyrosine kinase TKT by the Epstein-Barr virus transactivator Zta. J Virol. 2000;74(16):7391-7399. (Pubitemid 30613084)
21. Kung HJ, Chen HC, Robinson D. Molecular profiling of tyrosine kinases in normal and cancer cells. J Biomed Sci. 1998;5(2):74-78. (Pubitemid 28253096)
22. Liu MT, Chang YT, Chen SC, et al. Epstein-Barr virus latent membrane protein 1 represses p53- mediated DNA repair and transcriptional activity. Oncogene. 2005;24(16):2635-2646.
23. Chang Y, Chang SS, Lee HH, Doong SL, Takada K, Tsai CH. Inhibition of the Epstein-Barr virus lytic cycle by Zta-targeted RNAinterference. J Gen Virol. 2004;85(Pt 6):1371-1379. (Pubitemid 38807732)
24. Chua HH, Lee HH, Chang SS, et al. Role of the TSG101 gene in Epstein-Barr virus late gene transcription. J Virol. 2007;81(5):2459-2471.
25. Chang Y, Lee HH, Chang SS, et al. Induction of Epstein-Barr virus latent membrane protein 1 by a lytic transactivator Rta. J Virol. 2004;78(23):13028- 13036. (Pubitemid 39507810)
26. Narasimhan M, Ammanamanchi S. Curcumin blocks RON tyrosine kinase-mediated invasion of breast carcinoma cells. Cancer Res. 2008;68(13):5185-5192.
27. Brennan P, Mehl AM, Jones M, Rowe M. Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells. Oncogene. 2002;21(8):1263-1271. (Pubitemid 34185243)
28. Kutz H, Reisbach G, Schultheiss U, Kieser A. The c-Jun N-terminal kinase pathway is critical for cell transformation by the latent membrane protein 1 of Epstein-Barr virus. Virology. 2008;371(2):246-256. (Pubitemid 351173227)
29. Miller WE, Earp HS, Raab-Traub N. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol. 1995;69(7):4390-4398.
30. Kung CP, Raab-Traub N. Epstein-Barr virus latent membrane protein 1 modulates distinctive NF-kappaB pathways through C-terminus-activating region 1 to regulate epidermal growth factor receptor expression. J Virol. 2010;84(13):6605-6614.
31. Horikawa T, Sheen TS, Takeshita H, Sato H, Furukawa M, Yoshizaki T. Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am J Pathol. 2001;159(1):27-33. (Pubitemid 33704188)
32. Lu J, Lin WH, Chen SY, et al. Syk tyrosine kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell migration in epithelial cells. J Biol Chem. 2006;281(13):8806-8814. (Pubitemid 43847987)
33. Lin JH, Tsai CH, Chu JS, Chen JY, Takada K, Shew JY. Dysregulation of HER2/HER3 signaling axis in Epstein-Barr virus-infected breast carcinoma cells. J Virol. 2007;81(11):5705-5713. (Pubitemid 46847009)
34. Li Y, Mahajan NP, Webster-Cyriaque J, et al. The C-mer gene is induced by Epstein-Barr virus immediate- early protein BRLF1. J Virol. 2004;78(21):11778-11785. (Pubitemid 39390764)
35. Cheung RK, Dosch HM. The tyrosine kinase lck is critically involved in the growth transformation of human B lymphocytes. J Biol Chem. 1991;266(14):8667-8670. (Pubitemid 21906563)
36. Liu R, Gong M, Li X, et al. Induction, regulation,and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma. Blood. 2010;116(2):297-305.
37. Kung CP, Raab-Traub N. Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor through effects on Bcl-3 and STAT3. J Virol. 2008;82(11):5486-5493. (Pubitemid 351705255)
38. Wang MH, Ronsin C, Gesnel MC, et al. Identification of the ron gene product as the receptor for the human macrophage stimulating protein. Science. 1994;266(5182):117-119. (Pubitemid 24345331)
39. Liu SL, Miller AD. Oncogenic transformation by the jaagsiekte sheep retrovirus envelope protein. Oncogene. 2007;26(6):789-801.
40. Klatt A, Zhang Z, Kalantari P, Hankey PA, Gilmour DS, Henderson AJ. The receptor tyrosine kinase RON represses HIV-1 transcription by targeting RNA polymerase II processivity. J Immunol. 2008;180(3):1670-1677.
41. Renne C, Willenbrock K, Kuppers R, Hansmann ML, Brauninger A. Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma. Blood. 2005;105(10):4051-4059. (Pubitemid 40656155)
42. Heslop HE. How I treat EBV lymphoproliferation. Blood. 2009;114(19):4002-4008.
43. Straathof KC, Savoldo B, Heslop HE, Rooney CM. Immunotherapy for post-transplant lymphoproliferative disease. Br J Haematol. 2002;118(3):728-740. (Pubitemid 35007376)
44. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant. 2005;5(12):2901-2906. (Pubitemid 43923950)
45. Zhang Y, Kaplan-Lefko PJ, Rex K, et al. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo. Cancer Res. 2008;68(16):6680-6687.
46. Eder JP, Shapiro GI, Appleman LJ, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res. 2010;16(13):3507-3516.